Skip to content

Application of TSPO-PET in Assessing Neuroinflammation in Bipolar II Disorder Patients

Application of TSPO-PET in Assessing Neuroinflammation in Bipolar II Disorder Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086968
Enrollment
Unknown
Registered
2024-07-16
Start date
2024-07-16
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar II Disorder

Interventions

Drug-Naive First-Episode Bipolar Disorder (BD) Patients Group:None
Health Control Group:None

Sponsors

The Third Xinagya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Age 13-45 years;2. Han Chinese, right-handed;3. Sufficient comprehension ability, education level = 4 years;4. Signed informed consent. Criteria for Inclusion of Drug-Naive First-Episode Bipolar Disorder (BD) Patients: 1. Meets DSM-5 criteria for Bipolar II Disorder;2. First episode, illness duration = 18 months;3. Currently in a depressive episode, with HAMD-24 score = 20;4. Never taken antidepressants or mood stabilizers.

Exclusion criteria

Exclusion criteria: 1. Severe physical illness, pregnancy, undergoing electroconvulsive therapy, or other MRI contraindications; 2. History of neurological diseases or unexplained comas; 3. Coexisting autoimmune diseases; 4. Symptoms related to inflammation (including fever, infectious diseases, or inflammatory conditions); 5. Coexisting other psychiatric disorders and Axis II disorders such as personality disorders or intellectual disabilities; 6. Recent (within 2 weeks) use of medications affecting mood or the immune system, such as corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and statins; 7. Coagulation disorders or vascular diseases, or taking anticoagulant medications; 8. History of substance abuse; 9. Alcohol consumption or benzodiazepine use within 1 week prior to the test; 10. Participation in a PET scan within the past year.

Design outcomes

Primary

MeasureTime frame
TSPO VT;Hamilton Depression Scale, HAMD;Self-Rating Depression Scale,SDS;HCL-32;Bech-Rafaelsdn Mania Rating Scale,BRMS;TSPO Polymorphism Genotyping;Cytokine;

Secondary

MeasureTime frame
Hamilton Anxiety Scale, HAMA;Self-Rating Anxiety Scale,SAS;Scale for Assessment of Positive Symptoms,SAPS;Scale for Assessment of Negtive Symptoms,SANS;Brief Psychiatric Rating Scale,BPRS;Childhood trauma questionnaire, CTQ;Family Environment Scale-Chinese Version,FES-CV;Rosenberg self-esteem scale, SES;Chinese Perceived Stress Scales,CPSS;Simplified Coping Style Questionnaire, SCSQ;Trail Making Test;Digital-Symbol Test;

Countries

China

Contacts

Public ContactWeidan Pu

The Third Xinagya Hospital of Central South University

weidanpu@csu.edu.cn+86 139 7519 6436

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026